Bevacizumab for Central Retinal Vein Occlusion Study

NCT00906685 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Central Retinal Vein Occlusion

Interventions

DRUG: bevacizumab
DRUG: Sham bevacizumab injection

Sponsor

Anders Kvanta